GLP‑1 real‑world data for obesity: A new standard for metabolic care
The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S....
The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S....
Recently, HealthVerity COO and co-founder Andrew Goldberg spoke at a timely webinar: Back to...
Why real-world data matters in epilepsy research Epilepsy affects millions of adults in the United...
Turning claims into interoperable evidence More means more. In a world where anyone can make...
Thank you for visiting HealthVerity at Fierce 2025 HealthVerity had a fantastic week at Fierce...
At HealthVerity, community is at the heart of who we are. Each year, our team members come together...
AI agents are quickly becoming part of the clinical conversation. Since the release of large...
Digital health innovators and pharma leaders are under increasing pressure to show that new models...
Recently, Omada Health and HealthVerity announced a press release highlighting their collaboration...
(Part 2) In Part 1 we explored how HealthVerity Marketplace delivers high-quality,...
The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S. have obesity, representing over 100 million patients.1 Not long ago, bariatric surgery was the only option for substantial weight loss among those with ...